about
Clinical Translation of Nanomedicine.Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors.Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer.Anticancer activity expressed by a library of 2,9-diazaperopyrenium dications.An improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIα and potent anticancer agent.Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES).Synthesis and biological characterization of protease-activated prodrugs of doxazolidineA Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of DoxorubicinOne-step fabrication of polymeric Janus nanoparticles for drug deliveryCanadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathiesRecent advances of cocktail chemotherapy by combination drug delivery systems.Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery.A mathematical model for thermosensitive liposomal delivery of Doxorubicin to solid tumour.Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling.
P2860
Q30355939-73D012A7-4EFA-4525-88BC-A909ED1CE77DQ33661049-D4174406-55A4-406A-BB51-86B5F6095495Q34053580-1BAB33E1-B3DD-4103-A44F-06A83B994CB9Q34082211-201E9F3B-E4F5-47B8-92EC-52D0CA44644EQ35130142-0425F092-7260-4DBC-8308-A12B811D9E3BQ35269036-9F9E4A19-1E9D-4A69-B7E9-E7E3AA902AC0Q35982475-578EC39F-4C12-4509-8B25-355EBEA767B4Q36206886-174E4265-D31E-4C96-9A74-BC736B4B3F61Q36446685-062686A8-8C6E-4253-9481-6FBFA4F806F2Q36638801-E35F8ABA-BEB2-41AA-A87A-FD307DF3D9E4Q37061992-D669F871-7B87-4B73-90F4-0A5012F37FE2Q37206908-B6D65557-4702-4E43-B6F5-BB312B83A131Q37459147-2140CBAD-1132-4C92-B820-69958203BC2FQ39030709-930E7351-C3A2-4D50-9660-B6ECAD9719EFQ41942293-CE5B68FA-0233-4737-9B49-87D7A94D6149Q55651995-F1EF8160-D8F2-4250-A0FF-BB54641154B9
P2860
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh
1983年學術文章
@zh-hant
name
Doxorubicin (adriamycin) cardiomyopathy.
@en
type
label
Doxorubicin (adriamycin) cardiomyopathy.
@en
prefLabel
Doxorubicin (adriamycin) cardiomyopathy.
@en
P2860
P1476
Doxorubicin (adriamycin) cardiomyopathy.
@en
P2093
P2860
P304
P407
P577
1983-09-01T00:00:00Z